Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
International Journal of Molecular Sciences|November 27, 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor MicroenvironmentAndrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
Targeted Oncology|February 12, 2024
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabMargherita Rimini, Eleonora Loi, Mario Domenico Rizzato, et al.
International Journal of Molecular Sciences|November 27, 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1Andrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
Cells|November 27, 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic CorrelationsAndrea Palicelli, Martina Bonacini, Stefania Croci, et al.
Cells|November 27, 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation VariablesAndrea Palicelli, Martina Bonacini, Stefania Croci, et al.
Frontiers in Oncology|August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysisAlessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Cancers|January 21, 2023
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation AnalysisRodolfo Sacco, Daryl Ramai, Raffaella Tortora, et al.
The Oncologist|March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selectionLetizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
Pageof 11